Neogen shares fell 7.22% after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination and at least 20 horse deaths.
NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Neogen (NASDAQ: NEOG) shares fell over 7% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths. If you bought NEOG and are now holding losses, you have legal rights. Investors who lost money on Neogen are encouraged to submit their loss information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
FDA testing reportedly identified multiple fungal species in HYCOAT -- a product marketed as sterile. Coverage of the FDA action cited nearly 100 affected horses. The decline was reported by several financial news outlets, including Seeking Alpha, Benzinga, and TipRanks.
HYCOAT is sold under the Neogen Vet brand, part of the Company's Animal Safety segment, which generated $54.5 million in revenue in the third quarter of fiscal 2026. Reports to date have not quantified potential fines, litigation costs, or reserve impacts tied to the HYCOAT matter. The Levi & Korsinsky investigation concerns potential securities law violations related to these events.
If you purchased Neogen stock and suffered a loss, start your NEOG loss review today or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the NEOG Investigation
Q: Who is conducting the NEOG investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased NEOG securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Who is eligible to participate in the NEOG investigation? A: Investors who purchased NEOG stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did NEOG stock drop? A: Shares fell approximately 7.22% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: What do NEOG investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my NEOG shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
jlevi@levikorsinsky.com \
Tel: (212) 363-7500\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-neog-securities-investigation-notice---levi--korsinsky-302900725.html
SOURCE Levi & Korsinsky, LLP
